ACT001

DRUG3 trials

Sponsors

Accendatech USA Inc., Nationwide Children's Hospital, National Neuroscience Institute

Conditions

Diffuse Intrinsic Pontine Gliomas (DIPG)H3K27-altered High Grade GliomaProgressive DIPGRecurrent DIPGRecurrent GlioblastomaRecurrent Glioblastoma Multiforme(GBM)Refractory DIPG

Phase 1

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Active, not recruitingNCT05053880

Accendatech USA Inc.Recurrent Glioblastoma Multiforme(GBM)

Start: 2021-09-22End: 2026-12-31Target: 48Updated: 2026-06-10

Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

RecruitingNCT06838676

Nationwide Children's HospitalDiffuse Intrinsic Pontine Gliomas (DIPG), H3K27-altered High Grade Glioma, Progressive DIPG +2

Start: 2025-07-10End: 2035-07-01Target: 60Updated: 2026-08-12

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

RecruitingNCT06894225

National Neuroscience InstituteRecurrent Glioblastoma

Start: 2025-03-22End: 2027-05-01Target: 12Updated: 2026-09-04